---
title: "New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295656799.md"
description: "A Tufts CSDD analysis reveals that AI agents in clinical development can generate up to $21 million in net financial value per drug program, achieving an 82x ROI. This finding, based on oncology data and industry experience, highlights significant cost efficiencies for Medable Inc.'s agentic clinical monitoring solutions."
datetime: "2026-08-12T11:04:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295656799.md)
  - [en](https://longbridge.com/en/news/295656799.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295656799.md)
generator: "portal-rs"
---

# New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI

In Palo Alto, California, Medable Inc. revealed a significant development in agentic clinical development. A recent analysis conducted by Tufts Center for the Study of Drug Development (CSDD) demonstrated that utilizing an AI clinical monitoring agent could yield substantial financial benefits. The study indicated that such an agent has the potential to generate net financial gains of up to $21 million per drug development program, translating to an impressive 82 times return on investment. These conclusions were drawn from assessed oncology program and clinical trial data provided by Tufts CSDD, in addition to contract value and industry experience.

## Related News & Research

- [NeuroThera Labs seeks FDA orphan drug status for adult Tourette treatment SCI-110](https://longbridge.com/en/news/297783543.md)
- [09:03 ETMasterClass Launches Understanding GLP-1s and Weight Loss, the Guidance That Should Come With Every GLP-1 Prescription¹](https://longbridge.com/en/news/297919061.md)
- [BioVersys says FDA grants Fast Track designation for BV100 antibiotic candidate](https://longbridge.com/en/news/297733781.md)
- [Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs | DTCFF Stock News](https://longbridge.com/en/news/297476847.md)
- [RCS - OptiBiotix Health - H&B launches FORMI™ Product containing SlimBiome®](https://longbridge.com/en/news/297738732.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**